Samsung Biologics receives 'Negligible Risk' ESG rating
Sustainalytics rated Samsung Biologics at 9.0, placing it among the top 0.5% in the pharmaceuticals industry.
Related stories
Microsoft Says Consumer Services Recovered, Enterprise Recovery Ongoing
Microsoft said its consumer products services had fully recovered at 4:10 p.m. UTC Friday, while Microsoft 365 enterprise services were seeing some sustained recovery. The company
M impact | EQUITY | Nov 14, 2026, 05:32 AM UTC
Microsoft Says Consumer Products Services Recovered
Microsoft said its consumer products services had fully recovered, while Microsoft 365 enterprise services were seeing a sustained recovery.
M impact | EQUITY | Nov 14, 2026, 05:17 AM UTC
Microsoft restores consumer product services after outage
Microsoft said its consumer product services have been restored; other services are not included in the update.
M impact | EQUITY | Nov 14, 2026, 05:10 AM UTC
Microsoft Outlook Begins Returning After Global Microsoft 365 Disruption
Microsoft said it was working to restore email access after a global Microsoft 365 disruption. Industry executives warned of risks from dependence on a single technology provider.
M impact | EQUITY | Nov 14, 2026, 04:31 AM UTC
Tesla sells Cybercab to first private customers
Reuters reports Tesla is offering its Cybercab to its first private customers.
M impact | EQUITY | Nov 14, 2026, 04:23 AM UTC
Microsoft says affected services fully recovered
L impact | EQUITY | Nov 14, 2026, 04:14 AM UTC